Clinical Trial

Transnasal Sphenopalatine Ganglion Block for Postoperative Pain and Recovery in Tonsillectomy (TONwoPA)

Study acronym: TONwoPA
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this clinical trial is to evaluate the effectiveness of transnasal transmucosal sphenopalatine ganglion block in reducing post-tonsillectomy pain. The study also investigates its impact on rescue analgesic requirements and postoperative recovery by comparing 5% lidocaine with placebo. Participants will receive a transnasal transmucosal sphenopalatine ganglion block with either 5% lidocaine or placebo (saline). Postoperative pain levels and opioid consumption will be monitored during the first 24 hours after surgery. In addition, length of hospital stay, the occurrence of primary and secondary post-tonsillectomy hemorrhage up to 14 days, unplanned hospital readmissions after discharge, and patient satisfaction on postoperative day 14 will be assessed.
Trial Details
NCT Number NCT07370129
Lead Sponsor Ankara University
Conditions Post Tonsillectomy Pain, Post Operative Analgesia, Opioid Consumption, Sphenopalatine Ganglion Block, Tonsillar Surgery Complications
Enrollment 28 participants
Start Date 2025-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-27